Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Emerging News
Emerging Companies Pursuing Ophthalmic Indications, December 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, November 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, October 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, September 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Tern Therapeutics Launches with $15 Million Financing and Pipeline in CLN2 Batten Disease
Tern Therapeutics announced its launch Aug. 27, along with closing of a $15 million financing. The company also reported that it had licensed gene therapy candidates RGX-381 and RGX-181 (now design...
Emerging Companies Pursuing Ophthalmic Indications, August 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, July 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
NexThera Files IND with US FDA for Trial of Wet AMD Eye Drop Candidate
NexThera, of Busan, South Korea, announced July 16 that it had filed an investigational new drug (IND) application with the US FDA for a Phase I/IIa trial of NT-101, an eye drop candidate for wet a...
China’s DP Technology Will Advance Oral Lp-PLA2 Inhibitor for DR and DME
China’s DP Technology announced July 8 that it would advance DPT0415, a novel small molecule targeting lipoprotein‐associated phospholipase A2 (Lp-PLA2), as a potential oral treatment candidate for...
Emerging Companies Pursuing Ophthalmic Indications, June 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, May 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, April 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis
Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...
Emerging Companies Pursuing Ophthalmic Indications, March 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
France’s PulseSight Therapeutics Launches to Advance Non-viral Retinal Gene Therapies
France’s PulseSight Therapeutics, developing non-viral ophthalmic gene therapies, launched Feb. 28 with an undisclosed seed financing from Pureos Bioventures and ND Capital. A spokeswoman for Pulse...
Emerging Companies Pursuing Ophthalmic Indications, February 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, January 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, December 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
India’s Enzene Biosciences Launches Ranibizumab Biosimilar for Wet AMD
Enzene Biosciences announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references Lucentis, which is sol...
Emerging Companies Pursuing Ophthalmic Indications, November 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, October 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, September 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Emerging Companies Pursuing Ophthalmic Indications, August 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.